AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 16.62 |
Market Cap | 2.81B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.78 |
PE Ratio (ttm) | 21.66 |
Forward PE | n/a |
Analyst | Buy |
Ask | 16.9 |
Volume | 2,046,131 |
Avg. Volume (20D) | 2,324,506 |
Open | 18.15 |
Previous Close | 17.90 |
Day's Range | 16.61 - 18.23 |
52-Week Range | 14.15 - 29.29 |
Beta | undefined |
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych...
Analyst Forecast
According to 18 analyst ratings, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 42.05% from the latest price.
Next Earnings Release
Analysts project revenue of $282.92M, reflecting a 22.45% YoY growth and earnings per share of 0.23, making a -17.86% decrease YoY.
1 month ago · businesswire.com
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial OfficerSAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead...
1 month ago · seekingalpha.com
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ETNUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growt...
1 month ago · businesswire.com
Acadia Pharmaceuticals to Participate at Upcoming Investor ConferencesSAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside ...